

Nidhi Tandon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9100402/publications.pdf>

Version: 2024-02-01

24
papers

263
citations

840776

11
h-index

940533

16
g-index

24
all docs

24
docs citations

24
times ranked

450
citing authors

#	ARTICLE	IF	CITATIONS
1	The evolution of stem-cell transplantation in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 123-133.	2.5	31
2	Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 35.	1.2	30
3	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	7.2	28
4	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	4.1	24
5	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 41.	6.2	24
6	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	7.2	20
7	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	2.5	17
8	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 455-464.	3.0	16
9	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E117-E120.	4.1	13
10	The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. <i>Leukemia</i> , 2018, 32, 1243-1246.	7.2	12
11	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	4.1	11
12	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	4.1	11
13	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	7.2	8
14	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188.	3.0	4
15	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.	2.4	4
16	Prospective evaluation of the utility of magnetic resonance imaging in patients with non-MRI conditional pacemakers and defibrillators. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2931-2939.	1.7	3
17	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3317-3317.	1.4	3
18	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018, 132, 4460-4460.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2082-2082.	1.4	1
20	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016, 128, 3272-3272.	1.4	1
21	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	1.4	1
22	Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 153-158.	0.6	0
23	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3338-3338.	1.4	0
24	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2187-2187.	1.4	0